Annuncio pubblicitario
Italia markets close in 4 hours 14 minutes

  • FTSE MIB

    34.174,54
    -96,58 (-0,28%)
     

  • Dow Jones

    38.460,92
    -42,77 (-0,11%)
     

  • Nasdaq

    15.712,75
    +16,11 (+0,10%)
     

  • Nikkei 225

    37.628,48
    -831,60 (-2,16%)
     

  • Petrolio

    82,88
    +0,07 (+0,08%)
     

  • Bitcoin EUR

    59.334,28
    -2.590,42 (-4,18%)
     

  • CMC Crypto 200

    1.349,11
    -33,46 (-2,42%)
     

  • Oro

    2.339,90
    +1,50 (+0,06%)
     

  • EUR/USD

    1,0726
    +0,0025 (+0,24%)
     

  • S&P 500

    5.071,63
    +1,08 (+0,02%)
     

  • HANG SENG

    17.284,54
    +83,27 (+0,48%)
     

  • Euro Stoxx 50

    4.949,31
    -40,57 (-0,81%)
     

  • EUR/GBP

    0,8574
    -0,0009 (-0,10%)
     

  • EUR/CHF

    0,9791
    +0,0007 (+0,08%)
     

  • EUR/CAD

    1,4662
    +0,0006 (+0,04%)
     

Beam Therapeutics to Participate in Upcoming Investor Conferences

Beam Therapeutics
·1 minuto per la lettura
Beam Therapeutics
Beam Therapeutics

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences:

  • 2022 Jefferies London Healthcare Conference (fireside chat) on Tuesday, November 15, 2022, at 8:00 a.m. GMT; and,

  • Evercore ISI Virtual HealthCONx Conference 2022 (fireside chat) on Thursday, December 1, 2022, at 8:50 a.m. ET.

Live webcasts will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentations.

ANNUNCIO PUBBLICITARIO

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Dan Budwick
1AB
dan@1abmedia.com